Results 111 to 120 of about 7,687,713 (299)

Isocyanate‐Modified Melatplatin(IV) Enhances Antitumor Efficacy via TCF4/COL6A3‐Mediated Extracellular Matrix Remodeling and cGAS‐STING Pathway Activation in Bladder Cancer

Advanced Science, EarlyView.
A series of melatonin‐conjugated platinum(IV) prodrugs was functionalized with isocyanate chains (compounds 5‒12). MP‐12C (compound 11) was identified as the lead candidate, with optimal potency and safety. MP‐12C exhibited greater efficacy than cisplatin by increasing intracellular uptake, reshaping the extracellular matrix, activating the cGAS‐STING ...
Linhui Wang, Xiaomeng Liu, Tao Zhu, Zirun Su, Ruiping Liu, Zhe Li, Kaixuan Du, Kaipeng Jia, Chong Fu, Yuda Lin, Zihan Xue, Zhe Zhang, Chong Shen, Yunkai Qie, Zhouliang Wu, Zhiheng Liu, Kangkang Liu, Jingyuan Xu, Hailong Hu   +18 more
wiley   +1 more source

Plant Metabolites Screening Identifies 7‐epi‐10‐Deacetyltaxol Inhibiting Cell Division by Interfering With the Cell Cycle and Microtubule Organization

Advanced Science, EarlyView.
In this study, an efficient screening system is developed for plant metabolites to find a compound, 7‐epi‐10‐deacetyltaxol, inhibits tissue elongation. It suppresses plant growth through brassinosteroid and microtubule pathways. It is later applied to animal cells and human tumor organoids, resulting in similar cell division suppression. These findings
Yan‐Jie Zhang, Yu‐Xuan Bai, Geng G. Tian, Bin Zhang, Ding‐Yi Lu, Qing‐Ping Yao, Wen‐Hao Tian, Xiao‐Na Wei, Jing‐Ting Yang, Ze‐Yu Xiong, Yi Lu, Yu‐Tong Jiang, Chun‐Hui Cai, Yu‐Ming Lu, Xian‐Qing Jia, Li‐Li Jing, Bao‐Jun Yang, Ying‐Xin Qi, Xin‐Xin Han, Ji Wu, Wen‐Hui Lin   +20 more
wiley   +1 more source

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

Advanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen, Xinying Fu, Wenqian Dong, Xiaobei Deng, Simin Chen, Fujun Wang, Jian Zhao, Shiqun Shao, Liqiang Fan, Jingyu Zhang, Lixin Zhang   +10 more
wiley   +1 more source

Bioenergetic Materials for Tissue Regeneration: Modulating Metabolism to Promote Cellular Anabolism

Advanced Science, EarlyView.
Bioenergetic materials (BEMs) modulate cellular metabolism to promote tissue regeneration. Their principal mechanisms of action include metabolic substrate supplementation, metabolic enzyme modulation, organelle transfer, electrical current regulation, redox homeostasis modulation, and oxygen tension modulation.
Yuchen He, Yuwen Wang, Jonathan F. Gong, Yiting Lei, Fei Jin, Weihong Zhu, Rocky S. Tuan, Zhong Alan Li   +7 more
wiley   +1 more source

Tracking CDK1 Dynamics With a Novel Biosensor Mouse and Clinical Cohorts to Predict CDK4/6 Inhibitor Sensitivity in ER+ Breast Cancer

Advanced Science, EarlyView.
Cyclin‐dependent kinase (CDK) 1 activity is a dynamic marker of treatment response in estrogen receptor positive breast cancer. Patient cohorts reveal CDK1 activity increases during progression to invasive disease, where high expression correlates with poor survival. Using a novel Cdk1 biosensor mouse alongside in vitro models, we demonstrate that CDK1
Sarah Alexandrou, Kristine J. Fernandez, Min Li Huang, Ewan K. A. Millar, Claire Vennin, Leila Eshraghi, Tan Dat Timothy Lam, Victoria Lee, Nyah C. Brooks, Janett Stoehr, Cristian Guaman Mendez, Douglas Strathdee, David Stevenson, David Herrmann, Sandra O'Toole, Paul Timpson, Max Nobis, C. Elizabeth Caldon   +17 more
wiley   +1 more source

Ferroptosis Suppressor Protein 1 (FSP1)-CoQ10-NADPH-Axis Is Responsible for Erastin Resistance in MCF-7 Breast Cancer Cells

Antioxidants
Ferroptosis has emerged as a promising therapeutic strategy for drug-resistant cancers; however, the molecular mechanisms governing ferroptosis susceptibility in breast cancer remain poorly defined.
Brian B. Silver, Carri Murphy, Erik J. Tokar, Birandra K. Sinha   +3 more
doaj   +1 more source

Molecular profile and cell cycle in MCF-7 and MCF-7/Dox cells exposed to conventional and liposomal forms of doxorubicin.

Experimental oncology, 2009
To compare the molecular profile and cell cycle of sensitive and resistant to doxorubicin MCF-7 breast cancer cells upon exposition to conventional or liposome-encapsulated forms of doxorubicin.capital EM, Cyrilliccapital TE, Cyrilliccapital TE, Cyrillic-test, immunocytochemistry, flow cytometry.In sensitive MCF-7 cells the exposure to conventional but
Rusetskaya, N.V., Lukyanova, N.Yu., Chekhun, V.F.   +2 more
openaire   +2 more sources

Microscopic images of the MCF-7 and MCF-7-derived sphere cells and quantitative RT-PCR analysis of candidates.

, 2016
A. Parental MCF-7 cells. B. MCF-7-derived sphere cells. C. Quantitative RT-PCR results of six candidates (IL12RB2, CXCL1, CXCR4, ACADM, BCKDHB and HMGCS1). M indicates parental MCF-7 cells, and S indicates MCF-7-derived sphere cells.
Sang Jun Yoon (1805686), Sang Cheol Kim (137613), Jung-Ho Yoon (1805689), You-Sun Kim (236014), Johan Lim (517839), Jeong Hill Park (517837), Sung Won Kwon (498034), Won Jun Lee (517835)   +7 more
core   +1 more source

Transfer RNA‐Derived Small RNA‐5’tiRNAGln Drives HNRNPC Phase Separation to Promote Breast Cancer Bone Metastasis by Regulating IGF1R

Advanced Science, EarlyView.
This study reveals that 5'tiRNA‐Gln interacts with hnRNPC to promote IGF1R liquid‐liquid phase separation, which drives ERK1/2 signaling activation, EMT, and breast cancer bone metastasis. These findings highlight a novel mechanism of breast cancer bone metastasis and potential therapeutic target in metastatic breast cancer.
Bingnan Wang, Dongsong Liu, Xiaozhi Fan, Jiale Fan, Xuesi liu, Yu Wang, Zixin Wang, Mo Cheng, Ping Zhou, Wangjun Yan   +9 more
wiley   +1 more source

Cyclic Organoselenide BODIPY-Based Probe: Targeting Superoxide in MCF‑7 Cancer Cells

ACS Omega, 2020
Kashinath S. Madibone, Pratiksha P. Deshmukh, Ambuja Navalkar, Samir K. Maji, Purav M. Badani, Sudesh T. Manjare   +5 more
doaj   +1 more source